In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, The Associated Press reported erroneously on the nature of the FDA review. The FDA is considering an application for…

Email this Article
Add to del.icio.us
Add to digg
Add to Facebook




Food and Drug Administration – GlaxoSmithKline – Associated Press – Health – United States

View original here:
Correction: XenoPort-Glaxo drug